PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Deutsche Bank AG

Deutsche Bank AG raised its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 92.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,378 shares of the biopharmaceutical company's stock after acquiring an additional 45,310 shares during the quarter. Deutsche Bank AG owned approximately 0.12% of PTC Therapeutics worth $4,260,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in PTCT. Janney Montgomery Scott LLC increased its holdings in PTC Therapeutics by 8.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 5,965 shares of the biopharmaceutical company's stock valued at $269,000 after acquiring an additional 455 shares in the last quarter. KBC Group NV increased its holdings in PTC Therapeutics by 36.4% during the 4th quarter. KBC Group NV now owns 3,045 shares of the biopharmaceutical company's stock valued at $137,000 after acquiring an additional 813 shares in the last quarter. R Squared Ltd purchased a new position in PTC Therapeutics during the 4th quarter valued at about $79,000. China Universal Asset Management Co. Ltd. increased its holdings in PTC Therapeutics by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,353 shares of the biopharmaceutical company's stock valued at $738,000 after acquiring an additional 1,558 shares in the last quarter. Finally, Nadler Financial Group Inc. purchased a new position in PTC Therapeutics during the 4th quarter valued at about $223,000.

PTC Therapeutics Trading Up 0.9%

NASDAQ PTCT traded up $0.41 during trading hours on Friday, reaching $45.93. 782,553 shares of the company traded hands, compared to its average volume of 858,329. PTC Therapeutics, Inc. has a 12 month low of $28.72 and a 12 month high of $58.38. The stock has a market capitalization of $3.64 billion, a PE ratio of -7.73 and a beta of 0.52. The company has a 50 day moving average of $47.39 and a two-hundred day moving average of $47.41.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $9.19. The company had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $437.16 million. During the same quarter last year, the company earned ($1.20) earnings per share. The company's revenue was down 9.6% compared to the same quarter last year. On average, equities research analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Insider Buying and Selling at PTC Therapeutics

In other news, Director Stephanie Okey sold 5,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $54.00, for a total value of $270,000.00. Following the transaction, the director now directly owns 8,867 shares in the company, valued at approximately $478,818. This trade represents a 36.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Mark Elliott Boulding sold 15,521 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $53.30, for a total transaction of $827,269.30. Following the completion of the transaction, the vice president now owns 103,901 shares in the company, valued at approximately $5,537,923.30. The trade was a 13.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,264 shares of company stock worth $1,469,137 in the last ninety days. 5.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Royal Bank of Canada raised their target price on shares of PTC Therapeutics from $57.00 to $58.00 and gave the company an "outperform" rating in a report on Wednesday, May 7th. JPMorgan Chase & Co. lowered their price target on shares of PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Cantor Fitzgerald lowered their price target on shares of PTC Therapeutics from $113.00 to $112.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Bank of America upgraded shares of PTC Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $55.00 to $68.00 in a report on Friday, May 9th. Finally, Robert W. Baird lowered their price target on shares of PTC Therapeutics from $70.00 to $66.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $63.25.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.